

## PROTOCOL SUMMARY

# The quality of reporting of randomised controlled trials in asthma: systematic review protocol

Chara Ntala<sup>1</sup>, Panagiota Birmili<sup>1</sup>, Allison Worth<sup>2</sup>, Niall H Anderson<sup>2</sup>, \*Aziz Sheikh<sup>2</sup>

<sup>1</sup> University of Patras, Medical School, University Campus, PC 26504, Rio, Patras, Greece

<sup>2</sup> Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK

Received 23rd August 2012; revised 11th October 2012; accepted 12th October 2012; online 24th January 2013

© 2013 Primary Care Respiratory Society UK. All rights reserved.

C Ntala et al. *Prim Care Respir J* 2013; 22(1): PS1-PS8

<http://dx.doi.org/10.4104/pcrj.2013.00003>

**Keywords** asthma, randomised controlled trials

## Background

The randomised controlled trial (RCT) is the most robust design to assess the efficacy and effectiveness of treatments.<sup>1</sup> As a result of this realisation, clinical decision-making in recent years has been directed away from reliance based solely on the doctor's clinical experience towards a paradigm based on evidence derived from RCTs. The results of large RCTs have subsequently been translated into guidelines containing evidence-graded recommendations which clinicians are encouraged to use as the basis of good clinical practice.<sup>2</sup> If, however, the 'raw material' is flawed, the conclusions cannot be trusted, hence the need to appraise critically the quality of the underpinning trial evidence.<sup>3</sup>

Quality is a multidimensional concept which relates to the design, conduct, and analysis of a trial, its clinical relevance, and its reporting.<sup>3</sup> In most cases, the RCT report is the only source for clinicians, guideline developers, and other researchers to judge the validity and generalisability of the results, so the quality of reporting of trials is of inherent interest.<sup>4</sup> It is then of considerable concern that the quality of reporting of RCTs is often sub-optimal.<sup>5</sup>

In response to these concerns about the quality of reporting of RCTs, in the mid-1990s an international group developed the Consolidated Standards of Reporting Trials (CONSORT) Statement.<sup>6</sup> This was first published in 1996 and then updated in 2001.<sup>5</sup> After an expert meeting in January 2007, this was further revised resulting in the latest iteration – i.e. the CONSORT 2010 Statement.<sup>5</sup>

The current CONSORT Statement (hereafter referred to as CONSORT) comprises a checklist of essential items that should be included in reports of RCTs and a diagram for documenting the flow of participants through a trial. It is formulated primarily for use with reports of two-arm parallel-group RCTs. Many of the CONSORT data fields are, however, also relevant to a wider spectrum of trial designs

such as non-inferiority, equivalence, factorial, cluster, and crossover trials.<sup>5</sup> Extensions to the CONSORT checklist for reporting trials with some of these other designs have been published,<sup>7-9</sup> as have those for reporting particular types of data (i.e. harms<sup>10</sup>), types of interventions (i.e. non-pharmacological treatments<sup>11</sup> and herbal interventions<sup>12</sup>), and abstracts.<sup>13</sup> In this review we will, as appropriate, use the non-pharmacological, non-inferiority and equivalence, cluster and pragmatic extensions of CONSORT.

CONSORT criteria have been used to assess the reporting quality of RCTs in several disease areas<sup>4,14,15</sup> and journal types.<sup>16,17</sup> There have, however, been no recent assessments of the quality of RCTs reporting in the asthma literature. The only previous study on clinical trials of asthma treatments was undertaken for the period 1984–1997 and was published in 2002 in two reports.<sup>18,19</sup> This initially involved a comparison between RCTs published in Spanish and English language journals,<sup>19</sup> and this was then followed by a secondary analysis of a subsection of the same dataset focusing solely on the quality of RCTs in English.<sup>18</sup> The first article showed poorer reporting quality of the RCTs in Spanish publications and a strong association between the type of journal, type of intervention, and the comparison measure used and reporting quality. Moreover, this study highlighted the necessity for better reporting in general in the asthma literature, leading the authors to advocate the more widespread use of a checklist by authors and editors in order to improve reporting standards.<sup>19</sup>

Building on this earlier work, we will examine the quality of reporting of asthma clinical RCTs in the contemporary asthma literature. Our secondary aim is to investigate if there is an association between specific trial characteristics that have previously been identified in the literature in influencing reporting quality and the actual quality of the trial reports.<sup>4,14,17,20-22</sup>

\* **Corresponding author:** Professor Aziz Sheikh, Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG, UK. Tel: +44 (0)131 651 4151 Fax: +44 (0)131 650 9119 E-mail: [aziz.sheikh@ed.ac.uk](mailto:aziz.sheikh@ed.ac.uk)

## Objectives

The primary objective is to assess the contemporary quality of reporting of RCTs in the asthma literature for the period 2010–2012.

The secondary objectives are to identify factors associated with better reporting quality, that is:

- Are trials published in general medicine journals associated with better quality than those published in specialist journals?
- Is a high impact factor of the journal of publication associated with studies of better quality than those published in lower impact journals?
- Are studies conducted or led by teams in high income country settings (defined using World Bank Group definitions)<sup>23</sup> associated with better quality than those in middle and low income country settings?
- Does the funding source have an impact on study quality?
- Are trials evaluating a pharmacological intervention associated with better quality than those evaluating a non-pharmacological intervention?
- Are studies with multiple participating centres associated with better quality than single-centre studies?

## Review methods

### Search strategy

We will search the electronic database MEDLINE (via Ovid) using the search terms of the Cochrane Airways Group Specialised Register for asthma and RCTs for the time period January 2010 to July 2012. We will include studies that have been published in the top 10 impact factor journals in general medicine and respiratory specialty journals using the most recent available (i.e. 2011) rankings,<sup>24</sup> as long as they publish clinical trials and include articles related to asthma. Our complete search strategy is presented in Appendix 1.

### Inclusion criteria

- Types of studies: RCTs with parallel or cluster study design that involve only human subjects
- Types of participants: All study populations with asthma as the only condition being examined
- Types of interventions: Pharmacological and non-pharmacological interventions evaluating the clinical effectiveness of a treatment with any conceptual framework (superiority, non-inferiority, equivalence). We consider that a trial is evaluating the effectiveness of a treatment as long as it has at least one clinical outcome (primary or secondary).

### Exclusion criteria

- Reviews, systematic reviews, and meta-analyses
- Non-randomised trial designs (quasi-experimental, observational studies)
- Studies with crossover and factorial design, n-of-1 trials, split body trials
- Studies evaluating diagnostic tests, prevention, prognosis, cost-effectiveness, pathophysiological mechanisms, pharmacokinetics, pharmacogenetics, validation of questionnaires, tolerability of drugs, and economic studies
- Trials not reported as full papers (abstracts), editorials, comments, letters, case reports, audits, guidelines, historical

articles

- Methodological, epidemiological and qualitative studies
- Study protocols
- Pilot studies and phase I, II, and IV trials
- Secondary analysis of trials
- Studies reporting updates of previously published RCTs.

### Review strategy

Searches will be undertaken independently by two reviewers (CN and PB) with support from AW and AS. The references will be imported into EndNote and duplicates will be deleted. Both reviewers will independently review the titles for potentially eligible studies. They will not be blinded to study details. If they are unsure or there are disagreements they will read the abstract also. Full text copies of potentially relevant studies will be obtained and CN and PB will assess their eligibility for inclusion against the criteria mentioned above. A kappa statistic will be calculated to measure the level of agreement.<sup>25</sup> Where the reviewers agree, they will either include or exclude the study as appropriate. Disagreements will be resolved through discussion with AW or AS as arbiters. The studies that will be excluded after reading the full paper ('near-misses') will be reported in a table with reasons for exclusion. The whole process will be documented on a PRISMA flow chart.<sup>26</sup>

### Data extraction and quality assessment strategy

Data will be extracted independently by two reviewers (CN and PB) from the selected studies using an appropriate electronic customised data extraction form (see Appendices 2–4). The reviewers will not be masked to study details. There will be pilot testing of the data extraction sheet, disagreements will be discussed, and modifications will be made if required. In case of multiple reports of the same study, we will extract data directly into a single data extraction form. Disagreements will be resolved through discussion with AS as arbiter. We will extract data on general characteristics of the trials (see Appendix 2) and use a modified 38-item CONSORT-based checklist (see Appendix 3) that consists of all the CONSORT checklist items plus one additional item from the non-pharmacological treatments extension. The assessment of the adequacy of reporting will be done according to the CONSORT 2010 guidelines and its extensions.<sup>5,8,9,11,12</sup> Each item can be characterised as 'yes' if it is clearly and adequately reported, or 'no' if it is partially unclear or not reported at all. If an item is not applicable to a specific study we will characterise it as 'N/A'. Each 'yes' answer will receive a score of 1 and each "no" answer will be scored as 0. The overall quality scoring of the trial will be calculated as a proportion of the 'yes' rated applicable items (possible range 0–38 points). In addition, we will score the overall quality of reporting using key parameters of internal validity summarised in the Cochrane Risk of Bias tool (see Appendix 4) and we will categorise the studies into those at (1) low risk of bias and (2) moderate/high risk of bias.<sup>25</sup>

The following data will be extracted:

General characteristics

- Journal name
- Journal type (general medicine or specialty)
- Journal impact factor
- Country of study (high-income, middle-income, low-income)

- Funding source (solely industry, part industry, non-industry, none, unknown)
- Trial design (parallel or cluster)
- Conceptual framework (superiority, non-inferiority, equivalence)
- Type of intervention (drug or non-pharmacological)
- Number of participating centres (multiple or single centre).

### Analysis and data synthesis

We will calculate the proportion of the trials that have clearly and adequately reported each CONSORT item with a 95% confidence interval (CI). An overall quality score will also be calculated for each trial as a percentage of all the adequately reported applicable items with a 95% CI, which will be used to inform a global assessment of the quality of reporting. The general characteristics data will be presented as numbers and percentages with 95% CI when categorical and as mean and SD or median and IQR with 95% CI when continuous. SPSS software will be used to identify the variables associated with 'low risk of bias' studies with Fisher's exact test, and overall quality scores for subgroups with different trial characteristics will be compared with appropriate two-sample methods (rank-based or Normality-based, depending on the distributional characteristics of the overall quality score). We will report on the quality of reporting of asthma trials and make recommendations for researchers and journal editors regarding the conduct, reporting, and publication of asthma trials. In our description of the studies we will make reference to the setting and population in which the study was undertaken. In concluding, we will consider the quality and relevance of the body of work for informing clinical decision-making.

**Handling editor** Anthony D'Urzo

**Acknowledgements** We are grateful to the following colleagues for their help in conducting the study: Marshall Dozier, Senior Liaison Librarian, for her contribution to the creation and implementation of the search strategy and data management, and Ulugbek Nurmatov, Clinical Research Fellow, for his advice on the data extraction and quality assessment tools.

**Conflicts of interest** The authors declare that they have no conflicts of interest in relation to this protocol. AS is Joint Editor-in-Chief of the *PCRJ*, but was not involved in the editorial review of, nor the decision to publish, this article.

**Contributorship** AS conceived the study; all authors developed the protocol and contributed to writing the protocol.

**Funding** CN's Erasmus LLP placement with The University of Edinburgh's Allergy and Respiratory Research Group was supported by the Erasmus-European Commission.

## References

1. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. *Control Clin Trials* 1995;**16**(1):62-73. [http://dx.doi.org/10.1016/0197-2456\(94\)00031-W](http://dx.doi.org/10.1016/0197-2456(94)00031-W)
2. Travers J, Marsh S, Williams M, *et al.* External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? *Thorax* 2007;**62**(3):219-23. <http://dx.doi.org/10.1136/thx.2006.066837>
3. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. *BMJ* 2001;**323**(7303):42-6. <http://dx.doi.org/10.1136/bmj.323.7303.42>
4. Rios LP, Odueyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. *J Clin Endocrinol Metab* 2008;**93**(10):3810-6. <http://dx.doi.org/10.1210/jc.2008-0817>
5. Moher D, Hopewell S, Schulz KF, *et al.* CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;**10**(1):28-55. <http://dx.doi.org/10.1016/j.ijsu.2011.10.001>
6. Begg C, Cho M, Eastwood S, *et al.* Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA* 1996;**276**(8):637-9. <http://dx.doi.org/10.1001/jama.276.8.637>
7. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. *JAMA* 2006;**295**(10):1152-60. <http://dx.doi.org/10.1001/jama.295.10.1152>
8. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. *BMJ* 2004;**328**(7441):702-08. <http://dx.doi.org/10.1136/bmj.328.7441.702>
9. Zwarenstein M, Treweek S, Gagnier JJ, *et al.* Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008;**337**:a2390. <http://dx.doi.org/10.1136/bmj.a2390>
10. Ioannidis JP, Evans SJ, Gotzsche PC, *et al.* Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004;**141**(10):781-8.
11. Boutron I, Moher D, Altman DG, Schulz KF, Ravard P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med* 2008;**148**(4):295-309.
12. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Ann Intern Med* 2006;**144**(5):364-7.
13. Hopewell S, Clarke M, Moher D, *et al.* CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 2008;**5**(1):e20. <http://dx.doi.org/10.1371/journal.pmed.0050020>
14. Lai R, Chu R, Fraumeni M, Thabane L. Quality of randomized controlled trials reporting in the primary treatment of brain tumors. *J Clin Oncol* 2006;**24**(7):1136-44. <http://dx.doi.org/10.1200/JCO.2005.03.1179>
15. Anttila H, Malmivaara A, Kunz R, Autti-Ramo I, Makela M. Quality of reporting of randomized, controlled trials in cerebral palsy. *Pediatrics* 2006;**117**(6):2222-30. <http://dx.doi.org/10.1542/peds.2005-1630>
16. Pienaar ED, Volmink J, Zwarenstein M, Swingler GH. Randomised trials in the South African Medical Journal, 1948-1997. *S Afr Med J* 2002;**92**(11):901-03.
17. Gluud C, Nikolova D. Quality assessment of reports on clinical trials in the Journal of Hepatology. *J Hepatol* 1998;**29**(2):321-7. [http://dx.doi.org/10.1016/S0168-8278\(98\)80021-4](http://dx.doi.org/10.1016/S0168-8278(98)80021-4)
18. Quinones D, Llorca J, Dierssen T, Delgado-Rodriguez M. Quality of published clinical trials on asthma. *J Asthma* 2003;**40**(6):709-19. <http://dx.doi.org/10.1081/JAS-120023494>
19. Quinones D, Llorca J, Prieto-Salceda D, Delgado-Rodriguez M. [Quality of clinical trials published in Spain on asthma in comparison to trials in English language journals]. *Arch Bronconeumol* 2002;**38**(12):574-9.
20. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in hepatology: predictors of quality. *Hepatology* 1999;**30**(5):1134-8. <http://dx.doi.org/10.1002/hep.510300510>
21. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. *BMJ* 2010;**340**:c723. <http://dx.doi.org/10.1136/bmj.c723>
22. Farrokhkar F, Chu R, Whitlock R, Thabane L. A systematic review of the quality of publications reporting coronary artery bypass grafting trials. *Can J Surg* 2007;**50**(4):266-77.
23. The World Bank Group. Countries and economies. 2012. <http://data.worldbank.org/country/> (accessed 26 July 2012).
24. Thomson Reuters. ISI Web of Knowledge Journal Impact Factors 2012. <http://wok.mimas.ac.uk/> (accessed 15 Aug 2012).
25. Higgins JPT GSe. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. [www.cochrane-handbook.org](http://www.cochrane-handbook.org).
26. Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009;**6**(7):e1000100. <http://dx.doi.org/10.1371/journal.pmed.1000100>

## Appendix 1: Details of search strategy

## MEDLINE 2010-present

1. exp Asthma/
2. asthma\$.mp.
3. (antiasthma\$ or anti-asthma\$).mp.
4. Respiratory sounds/
5. wheez\$.mp.
6. Bronchial Spasm/
7. bronchospas\$.mp.
8. (bronch\$ adj3 spasm\$).mp.
9. bronchoconstrict\$.mp.
10. exp Bronchoconstriction/
11. (bronch\$ adj3 constrict\$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial\$ or respiratory or airway\$ or lung\$) adj3 (hypersensitiv\$ or hyperreactiv\$ or allerg\$ or insufficiency)).mp.
15. **or/1-14**
16. clinical trial.pt.
17. (randomized or randomised).ab,ti.
18. placebo.ab,ti.
19. dt.fs.
20. randomly.ab,ti.
21. trial.ab,ti.
22. groups.ab,ti.
23. (cluster adj2 (design or random?ed)).mp.
24. **or/16-23**
25. **15 and 24**
26. Animals/
27. Humans/
28. **26 not (26 and 27)**
29. **25 not 28**
30. limit 29 to yr="2010 -Current"
31. "new england journal of medicine".jn.
32. lancet.jn.
33. jama.jn.
34. "annals of internal medicine".jn.
35. "plos medicine public library of science".jn.
36. british medical journal.jn.
37. "archives of internal medicine".jn.
38. canadian medical association journal.jn.
39. bmc medicine.jn.
40. mayo clinic proceedings.jn.
41. "american journal of respiratory & critical care medicine".jn.
42. thorax.jn.
43. european respiratory journal.jn.
44. chest.jn.
45. respiratory research.jn.
46. pulmonary pharmacology & therapeutics.jn.
47. "international journal of tuberculosis & lung disease".jn.
48. pediatric pulmonology.jn.
49. respiratory medicine.jn.
50. respirology.jn.
51. **31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50**
52. **30 and 51**

## Appendix 2: General characteristics of trials

General information		
Identification of reviewer		
Date of data extraction		
Study number-identifier		
Notes		
Author		
Article title		
Publication date		
General characteristics		Comments
Journal name		
Journal type	General medical Specialty	
Journal impact factor		
Country of study		
Funding source	Solely industry Part industry Non-industry None Unknown	
Trial design	Parallel Cluster	
Conceptual framework	Superiority Non-inferiority Equivalence	
Type of intervention	Drug Non-pharmacological	
Number of centres	Single Multiple	

## Appendix 3: Modified 38-Item CONSORT-based 2010 checklist

Section/topic	Item no	Description	Adequately reported	Comments
Title and abstract	1	Identification as a randomised trial in the title	Yes/No	N/A
	2	Structured summary of trial design, methods, results, and conclusions	Yes/No	
<b>Introduction</b>				
Background and objectives	3	Scientific background and explanation of rationale	Yes/No	
	4	Specific objectives or hypotheses	Yes/No	
<b>Methods</b>				
Trial design	5	Description of trial design (such as parallel, factorial) including allocation ratio	Yes/No	
	6	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Yes/No	
Participants	7	Eligibility criteria for participants	Yes/No	
	8	Settings and locations where data were collected	Yes/No	
Interventions	9	Interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Yes/No	
Outcomes	10	Completely defined pre-specified primary and secondary outcome measures including how and where they were assessed	Yes/No	
	11	Any changes to trial outcomes after the trial commenced, with reasons	Yes/No	
Sample size	12	How was sample size determined	Yes/No	
	13	When applicable, explanation of any interim analyses and stopping guidelines	Yes/No	
<b>Randomisation</b>				
Sequence generation	14	Method used to generate the random allocation sequence	Yes/No	
	15	Type of randomisation; details of any restriction (such as blocking and block size)	Yes/No	
Allocation concealment mechanism	16	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Yes/No	
Randomisation implementation	17	Who generated the random allocation sequence who enrolled participants, and who assigned participants to interventions	Yes/No	
Blinding	18	If done, who was blinded after assignment to interventions (e.g. participants, care providers, those assessing outcomes) and how	Yes/No	
	19	If relevant, description of the similarity of interventions	Yes/No	
Statistical methods	20	Statistical methods used to compare groups for primary and secondary outcomes	Yes/No	
	21	Methods for additional analyses such as subgroup analyses and adjusted analyses	Yes/No	
<b>Results</b>				
Participant flow	22	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Yes/No	
	23	For each group, losses and exclusions after randomisation, together with reasons	Yes/No	
Implementation of interventions	24	Details of the experimental treatment and comparator as they were implemented	Yes/No	

## Appendix 3: Modified 38-Item CONSORT-based 2010 checklist continued

Section/topic	Item no	Description	Adequately reported	Comments
Recruitment	25	Dates defining the periods of recruitment and follow-up	Yes/No	
	26	Why the trial ended or was stopped	Yes/No	
Baseline data	27	A table showing baseline demographic and clinical characteristics for each group	Yes/No	
Numbers analysed	28	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Yes/No	
Outcomes and estimation	29	For each primary and secondary outcome, results for each group and the estimated effect size and its precision (such as 95% confidence interval)	Yes/No	
	30	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Yes/No	
Ancillary analyses	31	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Yes/No	
Harms	32	All important harms or unintended effects in each group	Yes/No	
<b>Discussion</b>				
Limitations	33	Trial limitations, addressing sources of potential bias, imprecision and, if relevant, multiplicity of analyses	Yes/No	
Generalisability	34	Generalisability (external validity, applicability) of the trial findings	Yes/No	
Interpretation	35	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Yes/No	
<b>Other information</b>				
Registration	36	Registration number and name of trial registry	Yes/No	
Protocol	37	Where the full trial protocol can be accessed, if available	Yes/No	
Funding	38	Sources of funding and other support (such as supply of drugs), role of funders	Yes/No	

## Appendix 4: Risk of Bias tool

Item	Judgement	Description
Adequate sequence generation?	Yes	Quote:
	No	Comment:
	Unclear	
Allocation concealment?		
Blinding of participants and healthcare providers?		
Blinding of outcome assessors and data analysts?		
Incomplete outcome data addressed?		
Free of selective reporting?		
Free of other bias?		